Navigation Links
Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S.,Phase I REOLYSIN Trial

CALGARY, June 05, 2007 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") announced today positive results from its U.S. Phase I clinical trial examining the systemic administration of REOLYSIN(R) in patients with advanced cancers. The results indicate that REOLYSIN(R) can be delivered systemically to patients with advanced and metastatic cancers and cause anti-tumour activity.

"REOLYSIN(R) administered as a one-hour infusion on a monthly schedule is safe and well-tolerated even in multiple doses," said Principal Investigator Dr. Sanjay Goel of the Montefiore Medical Center and Albert Einstein College of Medicine, New York. "This preliminary data suggests there is anti-tumour activity of REOLYSIN(R) administered as a single agent, and warrants further studies either alone or in combination with cytotoxic chemotherapy, which are currently being planned."

A total of 18 patients were treated in the escalating dosage trial to a maximum daily dose of 3x10(10) TCID(50) in a one-hour infusion. Of the 18 patients treated, eight demonstrated stable disease as measured by RECIST (Response Evaluation Criteria in Solid Tumours) including a patient with progressive breast cancer who experienced a 28.5% shrinkage in tumour volume. The trial was originally designed to demonstrate the safety of a single, one-hour infusion of REOLYSIN(R). During the treatment of the 4th cohort of patients however, Oncolytics applied for and was granted approval to allow subsequent patients to receive repeat monthly treatments of REOLYSIN(R). Of the patients eligible for retreatment, three patients received a range of two to seven one-hour infusions of REOLYSIN(R).

Toxicities possibly related to REOLYSIN(R) treatment in this trial were generally mild (grade 1 or 2) and included chills, fever and fatigue.

The primary objective of the Company's U.S. Phase I trial is to determine the maximum tolerated dose,
'"/>




Page: 1 2 3

Related medicine technology :

1. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2

Post Your Comments:
(Date:11/25/2009)...RNewswire/--TheFDAgrantedtraditionalapprovalforINT...ersetranscriptaseinhibitor(NNRTI).INTELENCEistheon...riencedadultswhoareexperiencingvirologicfailurewit...ral(ARV)agents.Thetraditionalapprovalisbasedon48-w...INTELENCEiscurrentlymarketedintheU.S.byTibotecTher...
(Date:11/25/2009)...Newswire-USNewswire/--RemediumTechnologiesInc.,aco...rebleeding,wonfirstprizeand$10,000intheMostPromisi...2009,companyofficialsannouncetoday. ,, Selected...steampitchedtheirinventionattheGSCSecuritySummitco...edium( www.remediumtechnologies.com )isdevelopinga...
(Date:11/25/2009)...PRNewswire/--RegadoBiosciences,aprivatelyheldcompa...hactivecontrolagents,announcedthatDavidMazzo,PhD,C...stAnnualHealthCareConferenceattheNewYorkPalaceHote...1:10pm(EST)onTuesday,December1andwillincludeanover...elopmentprogram,theanticoagulantsystem,REG1.Thehea...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2New Compact and Folding Reading Glasses from VisAcuity com 3A Never Leave Home Without Them 47465 1New Compact and Folding Reading Glasses from VisAcuity com 3A Never Leave Home Without Them 47465 2Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan 47462 1Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan 47462 2Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan 47462 3Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan 47462 4PLUS Diagnostics First National Laboratory to Offer Highly Specialized Gastrointestinal Tests 47459 1PLUS Diagnostics First National Laboratory to Offer Highly Specialized Gastrointestinal Tests 47459 2
...d at 2008 ICAAC/IDSA Joint Meeting, ROCKVILLE, Md...armaceutical company focused on commercializing,pr...tential, announces the,successful demonstration of... inhibitory concentration (MIC) resulting from in ... candidate, SQ109, and Tibotec,s lead TB,drug cand...
...rmAthene, Inc.,(NYSE ALTERNEXT US: PIP), a biodefe...inst biological and chemical threats, today announ...Phase I clinical trial,evaluating Protexia(R) for ...ch is produced in the milk of transgenic goats, is...ase (BChE), which has been shown to be effective,i...
Other Medicine Technology:Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 3PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 4PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 5
(Date:11/25/2009)...at colorectal cancer also can reverse a rare stoma...erapy for the disease, researchers at Vanderbilt U...ier,s disease causes thickening of the stomach lin...s well as anemia and swelling in the feet and ankl...risk for gastric cancer. Previously, the only effe...
(Date:11/25/2009)...d under the skin kill tumor cells, study finds , ...A cancer vaccine delivered in a fingernail-size im...udy reports. , The method uses polymer disks, 8...umor-specific antigens and implanted under the ski... The Harvard University scientists who developed t...
(Date:11/25/2009)... Nationwide Imaging Services, known as one of...iagnostic imaging equipment, now offering a total ...cing options, service and installation with acquis...echnologies of California) , ...ide Imaging Services is proud to announce its acqu...
(Date:11/25/2009)... BioSpace.com, the premier resource for life ...d edition of the BioForest™ Hotbed Campaign ..., CO (Vocus) November 25, 2009 -- BioSpace.com, th...formation, unveiled the third edition of the BioFo...,This regional campaign is a promotional effort hi...
(Date:11/25/2009)...ethertoShareRecordsSafely,ImproveCare ,, WASH...tofVeteransAffairs(VA)andKaiserPermanentetodayanno...icestoourNation,sheroes.VAandKaiserPermanentearela...rd(EHR)informationusingtheNationwideHealthInformat...umanServices. ,, "Theabilitytosharecriticalheal...
Breaking Medicine News(10 mins):Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 2Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 3Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2Health News:VA and Kaiser Permanente Invite Veterans to Participate in Health Record Pilot Program 2
... was warned about the rising number of Internet ga... Jan Wise, from London at the association's annual... implemented to track down and help addicts. Both ...to 15 year-olds show signs of addiction and 75 % a...
...titute of Health and Welfare (AIHW) it is found th...ber of negligence claims//. A new report show...epartment. Data was collected from 2002 when the m...octors were threatening to quit their jobs. T...
...oiding house dust mite allergens from the time of ...ema or atopy in high-risk children. Furthermore... of fish rich in omega-3 fatty acids was also foun...umption of omega-3 fatty acids, which are found in...
...ould help people lose weight, will be launched in ...ht loss preparation that controls //the desire to ... patients will be the first ones worldwide to have...essing the appetite. It is the first drug of its k...
...ndia by the George Institute for International Hea...dia were at a higher risk of developing lifestyle .... In a developing area of Andhra Pradesh, abou... studies have highlighted the escalating problem o...
...hat the insurance industry is unfair in dealing wi...g denied// travel insurance or are being asked to ...are disease free. A survey conducted by the ...th a pre-existing condition is treated the same. ...
Other Medicine News:Health News:Preventive Measures Proved Ineffective in Allergic Children 2Health News:Wonder Drug For Weight Loss Launched In UK 2Health News:Alarming Rise of Diabetes in Rural India - Survey Reports 2
Neumann Tying Forceps - Straight
Neumann Tying Forceps - Angled
Shepard Straight Tying Forceps
Shepard Curved Tying Forceps
Medicine Products: